NEVVI Medicare utilization intelligence

← back

BEHRENS, ROBERTMD NPI 1215999800 Clinician

Medical Oncology · DES MOINES, IA

Specialty Medical Oncology — from billed Medicare claims
Trained UNIVERSITY OF IOWA, RJ & L CARVER COLLEGE OF MEDICINE — medical school, self-reported to CMS
In practice about 29 years since medical school (class of 1997, self-reported to CMS)
Location DES MOINES, IA · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 80 codes billed · 387,870 disclosed services (CY2024 — most recent year in data)
Current groups
member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Group affiliation since 2019

20192026
STATE UNIVERSITY OF IOWA
2025–2026
ST ANTHONY REGIONAL HOSPITAL AND NURSING HOME
2019–2026
MISSION CANCER AND BLOOD, PLLC
2019–2024

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2025-02

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J9299 Injection, nivolumab, 1 mg
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9263 Injection, oxaliplatin, 0.5 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9025 Injection, azacitidine, 1 mg
J0185 Injection, aprepitant, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9264 Injection, paclitaxel protein-bound particles, 1 mg
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J9075 Injection, cyclophosphamide, not otherwise specified, 5 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J9173 Injection, durvalumab, 10 mg
J9041 Injection, bortezomib, 0.1 mg
J0897 Injection, denosumab, 1 mg
J0461 Injection, atropine sulfate, 0.01 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
Q5114 Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
J0640 Injection, leucovorin calcium, per 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J9190 Injection, fluorouracil, 500 mg
J9206 Injection, irinotecan, 20 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J9181 Injection, etoposide, 10 mg
J9045 Injection, carboplatin, 50 mg
80053 Blood test, comprehensive group of blood chemicals
96375 Injection of additional new drug or substance into vein
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
36415 Insertion of needle into vein for collection of blood sample
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
82784 Gammaglobulin (immune system protein) measurement
J1200 Injection, diphenhydramine hcl, up to 50 mg
96361 Infusion into a vein for hydration, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
96372 Injection of drug or substance under skin or into muscle
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3480 Injection, potassium chloride, per 2 meq
J3475 Injection, magnesium sulfate, per 500 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J3489 Injection, zoledronic acid, 1 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J3490 Unclassified drugs
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96411 Administration of additional new drug or substance into vein using push technique
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96360 Infusion into a vein for hydration, 31-60 minutes
J7030 Infusion, normal saline solution , 1000 cc
83615 Lactate dehydrogenase (enzyme) level
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
84439 Thyroxine (thyroid chemical), free
84443 Blood test, thyroid stimulating hormone (tsh)
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
82378 Carcinoembryonic antigen (cea) protein level
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96409 Administration of chemotherapy into vein using push technique
82728 Ferritin (blood protein) level
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
83540 Iron level
83550 Iron binding capacity
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
82607 Cyanocobalamin (vitamin b-12) level
82746 Folic acid level, serum
84153 Psa (prostate specific antigen) measurement, total
99239 Hospital discharge day management, more than 30 minutes
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.